{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:48:25Z","timestamp":1791186505431,"version":"4.1.0"},"reference-count":38,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2014,4,30]],"date-time":"2014-04-30T00:00:00Z","timestamp":1398816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hepatic diseases, like viral hepatitis, autoimmune hepatitis, hereditary hemochromatosis, non-alcoholic fatty liver disease (NAFLD) and Wilson\u2019s disease, play an important role in the development of liver cirrhosis and, hence, hepatocellular carcinoma. In this review, the current treatment options and the molecular mechanisms of action of the drugs are summarized. Unfortunately, the treatment options for most of these hepatic diseases are limited. Since hepatitis B (HBV) and C (HCV) infections are the most common causes of liver cirrhosis and hepatocellular carcinoma, they are the focus of the development of new drugs. The current treatment of choice for HBV\/HCV infection is  an interferon-based combination therapy with oral antiviral drugs, like nucleos(t)ide analogues, which is associated with improving the therapeutic success and also preventing the development of resistances. Currently, two new protease inhibitors for HCV treatment are expected (deleobuvir, faldaprevir) and together with the promising drug, daclatasvir (NS5A-inhibitor, currently in clinical trials), adequate therapy is to be expected in due course (circumventing the requirement of interferon with its side-effects), while in contrast, efficient HBV therapeutics are still lacking. In this respect, entry inhibitors, like Myrcludex B, the lead substance of the first entry inhibitor for HBV\/HDV (hepatitis D) infection, provide immense potential. The pharmacokinetics and the mechanism of action of Myrcludex B are described in detail.<\/jats:p>","DOI":"10.3390\/ijms15057500","type":"journal-article","created":{"date-parts":[[2014,4,30]],"date-time":"2014-04-30T13:16:54Z","timestamp":1398863814000},"page":"7500-7512","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Current Status in the Therapy of Liver Diseases"],"prefix":"10.3390","volume":"15","author":[{"given":"Philipp","family":"Uhl","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400,  69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Fricker","sequence":"additional","affiliation":[{"name":"Ruprecht-Karls-University, Institute of Pharmacy and Molecular Biotechnology,  Im Neuenheimer Feld 329, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Haberkorn","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400,  69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Mier","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400,  69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2014,4,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nri1573","article-title":"Immunology of hepatitis B virus and hepatitis C virus infection","volume":"5","author":"Rehermann","year":"2005","journal-title":"Nat. Rev. Immunol"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"Perz","year":"2006","journal-title":"J. Hepatol"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/hep.1840190629","article-title":"Classification of chronic hepatitis: Diagnosis, grading and staging","volume":"19","author":"Desmet","year":"1994","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1586\/14760584.4.4.459","article-title":"Prevention of hepatitis A by Havrix\u2122: A review","volume":"4","year":"2005","journal-title":"Expert Rev. Vaccines"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/386088a0","article-title":"Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy","volume":"386","author":"Wynne","year":"1997","journal-title":"Nature"},{"key":"ref_6","unstructured":"Mutschler, E. (2013). Arzneimittelwirkungen. Lehrbuch der Pharmakologie und Toxikologie, Wissenschaftliche Verlagsgesellschaft mbH. [10th ed]. (In German)."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrgastro.2011.33","article-title":"Hepatitis B therapy","volume":"8","author":"Kwon","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0168-8278(96)80113-9","article-title":"Side effects of high-dose interferon therapy for chronic hepatitis C","volume":"25","author":"Okanoue","year":"1996","journal-title":"J. Hepatol"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: Update","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3748\/wjg.v13.i1.22","article-title":"Viral and cellular determinants involved in hepadnaviral entry","volume":"13","author":"Glebe","year":"2007","journal-title":"World J. Gastroenterol"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hep.26211","article-title":"Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts","volume":"58","author":"Schieck","year":"2013","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nbt1389","article-title":"Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein","volume":"26","author":"Petersen","year":"2008","journal-title":"Nat. Biotechnol"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Chen, P.J., and Wu, T.C. (2013). One step closer to an experimental infection system for Hepatitis B Virus? The identification of sodium taurocholate cotransporting peptide as a viral receptor. Cell Biosci, 3.","DOI":"10.1186\/2045-3701-3-2"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm.2341","article-title":"EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy","volume":"17","author":"Lupberger","year":"2011","journal-title":"Nat. Med"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nm.2581","article-title":"Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor","volume":"18","author":"Sainz","year":"2012","journal-title":"Nat. Med"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1073\/pnas.0500269102","article-title":"The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)","volume":"102","author":"Lisnock","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"N. Eng. J. Med"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","article-title":"Efficacy of boceprevir, An NS3 protease inhibitor, In combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial","volume":"376","author":"Kwo","year":"2010","journal-title":"Lancet"},{"key":"ref_19","first-page":"57","article-title":"Expert opinion on boceprevir-and telaprevir-based triple therapies of chronic hepatitis C","volume":"50","author":"Sarrazin","year":"2012","journal-title":"Z. Gastroenterol"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(13)60247-0","article-title":"JKSofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): An open-label, randomised, multicentre phase 2 trial","volume":"381","author":"Kowdley","year":"2013","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/hep.26641","article-title":"-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-na\u00efve genotype 1 hepatitis C: The randomized PILLAR study","volume":"58","author":"Fried","year":"2013","journal-title":"Hepatology"},{"key":"ref_22","unstructured":"Jensen, D., Asselah, T., Dieterich, D., Foster, G., Sulkowski, M., and Zeuzem, S. (2013, January 1\u20135). A pooled analysis of two randomized, double-blind, placebo-controlled Phase III trials (STARTVersol and 2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-na\u00efve patients with chronic hepatitis C genotype-1 infection. Washington, DC, USA."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa1213557","article-title":"Faldaprevir and deleobuvir for HCV genotype 1 infection","volume":"369","author":"Zeuzem","year":"2013","journal-title":"N. Eng. J. Med"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2012.09.037","article-title":"Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options","volume":"58","author":"Suzuki","year":"2012","journal-title":"J. Hepatol"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/nbt0412-300a","article-title":"First HEV vaccine approved","volume":"30","author":"Proffitt","year":"2012","journal-title":"Nat. Biotech"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa061847","article-title":"Safety and efficacy of a recombinant hepatitis E vaccine","volume":"356","author":"Shrestha","year":"2007","journal-title":"N. Eng. J. Med"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/jhep.2002.34944","article-title":"Diagnosis and treatment of autoimmune hepatitis","volume":"36","author":"Czaja","year":"2002","journal-title":"Hepatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","article-title":"Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis","volume":"139","author":"Manns","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0016-5085(99)70244-1","article-title":"Molecular medicine and hemochromatosis: At the crossroads","volume":"116","author":"Bacon","year":"1999","journal-title":"Gastroenterology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1136\/gut.2006.108613","article-title":"Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis","volume":"56","author":"Hutchinson","year":"2007","journal-title":"Gut"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N. Engl. J. Med"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/ajg.2009.67","article-title":"NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: An eleven-year follow-up study","volume":"104","author":"Adams","year":"2009","journal-title":"Am. J. Gastroenterol"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Eng. J. Med"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1055\/s-2000-9389","article-title":"Wilson\u2019s disease","volume":"20","author":"Loudianos","year":"2000","journal-title":"Semin. Liver Dis"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0140-6736(82)92201-2","article-title":"Treatment of Wilson\u2019s disease with trientine (triethylene tetramine) dihydrochloride","volume":"319","author":"Walshe","year":"1982","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/jhep.2003.50252","article-title":"A practice guideline on Wilson disease","volume":"37","author":"Roberts","year":"2003","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Eng. J. Med"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1200\/jco.2012.30.15_suppl.4115","article-title":"Efficacy, Safety, Tolerability and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study","volume":"30","author":"Bitzer","year":"2012","journal-title":"J. Clin. Oncol"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/15\/5\/7500\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:10:54Z","timestamp":1760217054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/15\/5\/7500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,30]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,5]]}},"alternative-id":["ijms15057500"],"URL":"https:\/\/doi.org\/10.3390\/ijms15057500","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,30]]}}}